Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kazunori Uenaka"'
Publikováno v:
Drug Metabolism and Pharmacokinetics. 51:100496
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad845ede462c5779a9ca882afec27690
https://doi.org/10.1016/j.dmpk.2023.100496
https://doi.org/10.1016/j.dmpk.2023.100496
Autor:
Yeul Hong Kim, Do Youn Oh, Daisuke Sakai, Se Hoon Park, Toshihiko Doi, Ayuko Yamamura, Akihito Tsuji, Yoon-Koo Kang, Sameera R. Wijayawardana, Xuejing Wang, Yoshito Komatsu, Shigenori Kadowaki, Kazunori Uenaka, Hyun Cheol Chung, Volker Wacheck
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Mesenchymal–epithelial transition factor (MET) is expressed in gastric cancer and associated with poor clinical outcomes. We assessed activity, safety, and pharmacokinetics of emibetuzumab, a bivalent monoclonal anti-MET antibody that block
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fabc71295777b3b55b258212288db31
https://doi.org/10.1007/s00280-017-3445-z
https://doi.org/10.1007/s00280-017-3445-z
Autor:
Akichika Ozeki, Kazunori Uenaka, Masako Nakano, Yuri Matsuyama, William Kielbasa, Mosun Ayan-Oshodi
Publikováno v:
Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 48:131-139
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37562fca3531753d4df3d48fa610da06
https://doi.org/10.3999/jscpt.48.131
https://doi.org/10.3999/jscpt.48.131
Autor:
Masako, Nakano, Tomomi, Nakamura, Yasushi, Takita, Kazunori, Uenaka, Tomoaki, Ando, Michio, Senda, Abhinay D, Joshi, Ming, Lu, Christopher, Breault, Michael J, Pontecorvo
Publikováno v:
Annals of nuclear medicine. 33(8)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8da52a79d87de76f931f7c4f93397587
https://pubmed.ncbi.nlm.nih.gov/31140155
https://pubmed.ncbi.nlm.nih.gov/31140155
Autor:
Kensei Tobinai, Kazunori Uenaka, Tsuyoshi Ishiki, Soshi Nagaoka, Shinsuke Iida, Hiroya Asou, Kaijiro Maeda, Daisuke Ogiya, Masafumi Taniwaki, Yasunobu Abe, Ilaria Conti
Publikováno v:
Cancer Science
B-cell activating factor (BAFF) promotes the survival and adhesion of multiple myeloma (MM) cells. Tabalumab (LY2127399) is an anti-BAFF monoclonal antibody. This phase 1, multicenter, open-label, nonrandomized, dose-escalation study evaluated the sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7a88b4bdfa482529888010d8bb1968f
https://doi.org/10.1111/cas.13000
https://doi.org/10.1111/cas.13000
Autor:
Tomohide Tamura, Hiroshi Nokihara, Karim A. Benhadji, Noboru Yamamoto, Yasuhide Yamada, Kazunori Uenaka, Christopher A. Slapak, Risa Sekiguchi, Takeshi Makiuchi
Publikováno v:
Cancer Chemotherapy and Pharmacology. 71:1645-1655
LY2334737 is an oral gemcitabine prodrug. This Phase I study assessed the safety and tolerability of LY2334737 in Japanese patients with solid tumors and evaluated pharmacokinetics (PK), pharmacodynamics, and antitumor activity.Patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b944c284de0bbe968908a6b7c22fbe3
https://doi.org/10.1007/s00280-013-2165-2
https://doi.org/10.1007/s00280-013-2165-2
Autor:
Toshihiko Doi, Volker Wacheck, Hironobu Ohmatsu, Yoshitaka Zenke, Takashi Kojima, Hideaki Takahashi, Kiyotaka Yoh, Takashi Nakamura, Sotaro Enatsu, Kellie Turner, Kazunori Uenaka
Publikováno v:
Investigational New Drugs
SummaryBackground MET is a tyrosine kinase receptor involved in the regulation of cell proliferation and migration. Reported here are the phase I dose-escalation results for LY2875358, a monoclonal antibody against MET, in Japanese patients with adva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd624d09c435dc598650ee7afdca607c
https://pubmed.ncbi.nlm.nih.gov/27422720
https://pubmed.ncbi.nlm.nih.gov/27422720
Publikováno v:
Journal of Bone and Mineral Metabolism. 30:326-337
Teriparatide is an anabolic therapy for osteoporosis approved in the United States since 2002 and European Union since 2003; however, approval in Japan lagged significantly. This report describes analyses based on International Conference on Harmonis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03b977f6b5e3e6b211ac0d8bf2b11ef6
https://doi.org/10.1007/s00774-011-0314-4
https://doi.org/10.1007/s00774-011-0314-4
Autor:
Mark Fineman, Prajakti A. Kothare, Yoshitaka Isaka, Ayuko Yamamura, Helle Linnebjerg, Kwee Poo Yeo, Kazunori Uenaka, Hirofumi Shigeta, Choo Hua Teng, Kenneth F. Mace, Shin Irie, Amparo de la Peña, Yukikuni Sakata
Publikováno v:
The Journal of Clinical Pharmacology. 48:1389-1399
In this single-blind, parallel, placebo-controlled study, the pharmacokinetics, pharmacodynamics, tolerability, and safety of subcutaneous exenatide were evaluated in 40 Japanese patients with type 2 diabetes. Patients were allocated to 4 groups and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d81ade19a595626afc3882fa3126a67f
https://doi.org/10.1177/0091270008323750
https://doi.org/10.1177/0091270008323750
Publikováno v:
Folia Pharmacologica Japonica. 131:469-477
タダラフィル（シアリス®錠5 mg，10 mg，20 mg）は，強力かつ選択的なPDE5阻害作用を有する勃起不全（ED）治療薬である．In vitro試験系において，タダラフィルは強力なPDE5阻害作用を示した
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6254398a6e0468d5c5ab3c012e49a35b
https://doi.org/10.1254/fpj.131.469
https://doi.org/10.1254/fpj.131.469